Chung-Han Lee, MD, PhD

Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.

In the third article of this series, Chung-Han Lee, MD, PhD, gives an overview of non-clear cell renal cell carcinoma, discusses key clinical trial data, and looks to the future of renal cell carcinoma treatment.

Chung-Han Lee, MD, PhD, reviews clinical trial data and how they apply to the evolving treatment landscape in non-clear cell renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses the most important factors in treatment selection for later-line therapy in renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses the phase 2 KEYNOTE-B61 trial of pembrolizumab plus lenvatinib in patients with non–clear cell renal cell carcinoma.

An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.

Chung-Han Lee, MD, PhD, discusses the efficacy of a phase 2 study of pembrolizumab and lenvatinib in patient with metastatic clear cell renal cell carcinoma who have progressed on an immune checkpoint inhibitor.

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br /> &nbsp;